<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PDE4 inhibitor &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/pde4-inhibitor/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Sat, 17 Oct 2026 03:07:23 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.1.3</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>PDE4 inhibitor &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Topical Roflumilast: Why Route of Administration Rewrites the Safety Story</title>
		<link>https://bioengineer.org/topical-roflumilast-why-route-of-administration-rewrites-the-safety-story/</link>
		
		<dc:creator><![CDATA[]]></dc:creator>
		<pubDate>Sat, 17 Oct 2026 03:07:23 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[Atopic dermatitis]]></category>
		<category><![CDATA[considerations]]></category>
		<category><![CDATA[Dermatology]]></category>
		<category><![CDATA[drug safety]]></category>
		<category><![CDATA[managing]]></category>
		<category><![CDATA[PDE4 inhibitor]]></category>
		<category><![CDATA[pharmacists]]></category>
		<category><![CDATA[Pharmacokinetics]]></category>
		<category><![CDATA[Practical]]></category>
		<category><![CDATA[psoriasis]]></category>
		<category><![CDATA[roflumilast]]></category>
		<category><![CDATA[seborrheic dermatitis]]></category>
		<guid isPermaLink="false">https://bioengineer.org/?p=424538</guid>

					<description><![CDATA[A new pharmacokinetic review explains why the safety warnings attached to topical roflumilast, drawn largely from its oral COPD formulation, may overstate the real risks of the newly approved creams and foam for psoriasis, atopic dermatitis, and seborrheic dermatitis.]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">424538</post-id>	</item>
	</channel>
</rss>
